US pharma major Eli Lilly on Thursday launched the much-awaited diabetes and obesity management drug Mounjaro in India at one-fifth of US price. Lilly launched the drug in a single dose vial following ...

With diabetes and obesity cases surging in India, pharmaceutical giant Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight ...

Tirzepatide was evaluated in two robust global clinical development programs. (Image Credits: Pexels) Eli Lilly and Company (India) on Thursday announced the launch of Mounjaro in single-dose vial ...

Global demand for Lilly's diabetes and weight-loss drugs has soared, with the launch presenting a big market opportunity for the US-based drug company as India, world's most populous country ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Researchers have identified a boat-shaped mound in Turkey's Durupinar Formation, which has long been associated with the biblical story of Noah's Ark, The Jerusalem Post reported. The mound ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

It's very much my pleasure to welcome members of Lilly's leadership team to be here with us in Miami, and thank you for making the trip. So, to my right is Lucas Montarce who is the company's CFO ...

Virat Kohli had just sought a review. But, his eyes hollow, he knew the irrevocable fate of his. Kohli grimaced, shook his head in angst and stared ruefully at the twilight skies. The day was not to ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...